SciBac creates rEvolutionary live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. We improve beneficial microorganisms using our novel platform technology that can quickly, naturally, and safely transfer useful genetic traits. The resulting microorganism has all the best traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. By focusing on developing therapies for antibiotic resistant diseases, SciBac fills a rapidly increasing medical need.
SciBac’s first product targets the nation’s biggest antibiotic resistant threat, Clostridium difficile infection. Our microorganism strains out compete C. difficile by stopping colonization, neutralizing toxins, and directly killing the C. difficile organism. Unlike antibiotics, our product only targets C. difficile, allowing the rest of a patient’s microbiome to thrive, speeding up patient recovery and lowering the risk of recurrence.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 1828 El Camino Real, Burlingame,california 94010,united States
- Phone
- (650) 689-5343
- IN****@****BAC.COM
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- scibac.com
- HQ
- Burlingame, California
Scibac Questions
Scibac's helpline number is (650) 689-5343
Scibac's website is scibac.com
Scibac's LinkedIn profile is https://www.linkedin.com/company/scibac
Scibac has
2 employees.
View email and phone details for 2
employees at Scibac.
Scibac's industry is
Biotechnology Research
Scibac's top competitors are
Pulmobiotics Sl,
Retinalgenix Technologies, Inc.,
Pulmosim Therapeutics,
Sinopia Biosciences,
Qed Technologies,
Resolute Bio,
Reservoir Neuroscience,
Snap Bio, Inc.,
Senhwa Biosciences, Inc.,
Selva Therapeutics.
Scibac's support email address is INFO@SCIBAC.COM
Scibac's categories are Biotechnology Research
Scibac's founding year is 2015
